Otezla (Apremilast) Denied by Insurance

Otezla (apremilast) is an oral medication developed by Amgen (formerly Celgene/Bristol-Myers Squibb) that works by inhibiting phosphodiesterase 4 (PDE4), reducing the production of inflammatory cytokines associated with psoriasis and psoriatic arthritis. Unlike biologics, Otezla does not require injection, infusion, or laboratory monitoring for immunosuppression. It is FDA-approved for moderate-to-severe plaque psoriasis, active psoriatic arthritis, and oral ulcers associated with Behçet's disease. Its oral administration and relatively favorable safety profile make it an important step-down or step-therapy bridge option — and also a common target for insurer step therapy requirements before allowing access to more expensive biologics.

Why Insurance Denies Otezla

Step therapy requiring conventional DMARD failure first is the primary denial reason for Otezla, particularly for psoriatic arthritis. Many plans require documented failure of at least one conventional DMARD — typically methotrexate, sulfasalazine, or leflunomide — before approving Otezla. This is despite the fact that Otezla is itself a step therapy agent that insurers use as a prerequisite to biologic approval. The result: some patients are being denied Otezla while simultaneously being required to try it before their insurer will cover a biologic.

For psoriasis specifically, step therapy may require trial of topical treatments (corticosteroids, vitamin D analogs) and in some cases conventional systemic agents (methotrexate or cyclosporine) before Otezla is approved. This is clinically relevant because Otezla for psoriasis is generally intended for patients who have failed topical therapies, not as a first-line monotherapy.

Prior Authorization Denied: How to Appeal" class="auto-link">Prior authorization is required for Otezla despite its oral, non-biologic classification. Because it is a specialty drug, insurers require PA documentation including confirmed diagnosis, disease severity, prior treatment history, and physician attestation.

Not on formulary — some plans have removed Otezla from their specialty formulary, requiring a formulary exception on top of PA. This can occur when a plan's formulary committee decides preferred alternatives (including older, cheaper DMARDs) adequately serve the covered population.

Weight-based dosing and GI tolerability are sometimes cited in denial reviews if an insurer's clinical reviewer flags that Otezla is not appropriate for a specific patient based on GI side effect history or weight concerns — though this is an unusual basis for denial and is challengeable.

How to Appeal an Otezla Denial

Document conventional DMARD failure clearly. If your denial is based on missing DMARD trial documentation, provide records showing methotrexate, sulfasalazine, or leflunomide were tried — including start dates, doses, duration, and reason for discontinuation. Common reasons include: inadequate efficacy (persistent joint disease or skin involvement despite treatment), GI toxicity (particularly with methotrexate or sulfasalazine), liver enzyme elevation, bone marrow suppression, or contraindication (for example, methotrexate is contraindicated in pregnancy and in patients with significant hepatic disease or alcohol use).

Challenge circular step therapy requirements. If your insurer is simultaneously denying Otezla (requiring a DMARD first) and denying a biologic (requiring Otezla first), document this logical contradiction explicitly. Your physician should note in the medical necessity letter that the insurer's step therapy protocol is internally inconsistent and that resolution requires approving Otezla as the appropriate intermediate step.

Provide psoriasis or PsA severity documentation. For psoriasis, include PASI/BSA/DLQI scores. For PsA, include ACR response criteria documentation (joint counts, patient global assessment, physician global assessment, ESR/CRP). The insurer must understand the level of disease activity that conventional therapy has failed to control.

Emphasize Otezla's oral and safety advantages. Particularly for patients who cannot tolerate conventional DMARDs due to immunosuppression risk, hepatic concerns, or kidney function limitations, Otezla's non-immunosuppressive mechanism and avoidance of laboratory monitoring requirements are clinically meaningful. Your physician should document why Otezla is preferred over resuming or adjusting conventional DMARD therapy.

For Behçet's disease oral ulcers: Otezla is the first FDA-approved treatment for this indication. If your denial is for this indication, your physician should provide the Behçet's diagnosis documentation and note the absence of other FDA-approved alternatives.

Request peer-to-peer review. Rheumatologists and dermatologists can often resolve step therapy denials quickly through direct conversation with the insurer's medical reviewer, particularly when the clinical record clearly documents prior DMARD failure.

Patient Assistance Programs

Amgen offers Amgen SupportPlus, a patient assistance and copay support program. Commercially insured patients may qualify for copay assistance cards reducing their cost share. Qualifying uninsured or underinsured patients may receive Otezla at no cost. Visit amgensupportplus.com or call 1-888-OTEZLA-1.

Otezla's list price is approximately $30,000–$35,000 per year. While lower than biologic alternatives, this is still a significant specialty drug cost that makes patient assistance programs important.

Fight Back With ClaimBack

ClaimBack's free AI tool drafts a professional appeal letter in minutes, tailored to your insurer and denial reason. Don't let a denial be the final word.

Fight your denial at ClaimBack →

Related Reading:

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• What Is Step Therapy?